YM-155 potentiates the effect of ABT-737 in malignant humanglioma cells via survivin and Mcl-1 downregulation in an EGFR-dependent context

Esther P. Jane, Daniel R. Premkumar, Joseph D. DiDomenico, Bo Hu, Shi Yuan Cheng, Ian F. Pollack*

*Corresponding author for this work

Research output: Contribution to journalArticle

28 Scopus citations

Abstract

Antiapoptotic proteins are commonly overexpressed in gliomas, contributing to therapeutic resistance. We recently reported that clinically achievable concentrations of the Bcl-2/Bcl-xL inhibitor ABT-737 failed to induce apoptosis in glioma cells, with persistent expression of survivin and Mcl-1. To address the role of these mediators in glioma apoptosis resistance, we analyzed the effects of YM-155, a survivin suppressant, on survival on a panel of glioma cell lines. YM-155 inhibited cell growth and downregulated survivin and Mcl-1 in a dose- and cell line-dependent manner. While U373, LN18, LNZ428, T98G, LN229, and LNZ308cells exhibited an IC50 of 10 to 75 nmol/L, A172 cells were resistant (IC50 ~ 250 nmol/L). No correlation was found between sensitivity to YM-155 and baseline expression of survivin or cIAP-1/cIAP-2/XIAP. However, strong correlation was observed between EGF receptor (EGFR) activation levels and YM-155 response, which was confirmed using EGFR-transduced versus wild-type cells. Because we postulated that decreasing Mcl-1 expression may enhance glioma sensitivity to ABT-737, we examined whether cotreatment with YM-155 promoted ABT-737 efficacy. YM-155 synergistically enhanced ABT-737-induced cytotoxicity and caspasedependent apoptosis. Downregulation of Mcl-1 using short hairpin RNA also enhanced ABT-737-inducing killing, confirming an important role for Mcl-1 in mediating synergism between ABT-737 and YM-155. As with YM-155 alone, sensitivity to YM-155 and ABT-737 inversely correlated with EGFR activation status. However, sensitivity could be restored in highly resistant U87-EGFRvIII cells by inhibition of EGFR or its downstream pathways, highlighting the impact of EGFR signaling on Mcl-1 expression and the relevance of combined targeted therapies to overcome the multiple resistance mechanisms of these aggressive tumors.

Original languageEnglish (US)
Pages (from-to)326-338
Number of pages13
JournalMolecular cancer therapeutics
Volume12
Issue number3
DOIs
StatePublished - Mar 1 2013

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'YM-155 potentiates the effect of ABT-737 in malignant humanglioma cells via survivin and Mcl-1 downregulation in an EGFR-dependent context'. Together they form a unique fingerprint.

  • Cite this